RxDoctor Payments DataLook up a doctor →

Jonathan Weiss, MD

Dermatology · Snellville, GANPI 1619913712

Payments from drug & device makers

$2,408,026in general payments, 2019–2025

Across 2,193 payments — averaging $1098.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.1M
  • Galderma Laboratories, L.p.$131K
  • Biofrontera Bioscience GmbH$111K
  • AbbVie$108K
  • Endo Pharmaceuticals Inc.$106K
  • Biofrontera Inc.$95K
  • plus $738K from 46 others
$600in research payments, 2019–2025

Across 2 payments — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$600

What the payments were for

  • Consulting fees$277,23040%
  • Speaking & faculty fees$354,88851%
  • Grants$700%
  • Travel & lodging$11,4722%
  • Food & beverage$47,3977%
  • Education$6810%
  • Gifts$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,408,026 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$571,090
Medicare patients
1,344
Services billed
26,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$417,575
Cosentyx Unoready PenSecukinumab23$267,240
Dupixent PenDupilumab54$209,198
SotyktuDeucravacitinib29$184,149
Taltz AutoinjectorIxekizumab23$157,800
Humira(Cf) PenAdalimumab12$85,356
Clobetasol Propionate268$14,358
Doxycycline Ir-DrDoxycycline Monohydrate14$9,214
Doxycycline Hyclate373$7,076
Ivermectin14$5,189
Fluorouracil81$4,742
Dapsone19$2,533
Ketoconazole142$2,390
Betamethasone Valerate72$1,830
Triamcinolone Acetonide165$1,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$63,362$184,14929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 345 dermatology providers in Georgia.

Other dermatology in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →